Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials
Publication: ESMO Annals of Oncology, Breast cancer, early stage, Read More
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial
Publication: JAMA Network Open. 2024;7(11):e2447530. Authors: Laura J. van Read More
Incorporating Immunotherapy in the Management of Early-Stage Estrogen Receptor-Positive Breast Cancer
Publication: ESMO Open - Volume 9 - Issue 11 Read More
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers
Publication: Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1553. Read More
70โGene signatureโguided adjuvant systemic treatment adjustments in earlyโstage ER+ breast cancer patients: 7โyear followโup study
Title: 70โGene signatureโguided adjuvant systemic treatment adjustments in earlyโstage Read More
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
Publication: Heliyon 10 (2024) e39485 Authors: Daniele Generali, Andrea Read More
MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis
Publication: EMJ Oncol. 2024;12[1]:138-147. Authors: C. Jackisch, D. Pronin, Read More
Identification of Racial Disparities (ESMO 2024)
Publication: ESMO 2024 Authors: Sonya Reid, M.D., Jennifer G. Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreNSABP B-42 Trial shows MammaPrint Low Risk is Predictive of EET – JCO Publication
Journal of Clinical Oncology, July 24, 2024 Authors: Rastogi, et al.
Read More
